Please assess the completion status of the following clinical trial:

Trial Title: Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary disease is acute leukemia/MDS/CML~* Receiving allo-HSCT~Exclusion Criteria:~* cardiac dysfunction (particularly congestive heart failure)~* hepatic abnormalities (bilirubin ≥ 3 mg/dL, aminotransferase\> 2 times the upper limit of normal)~* renal dysfunction (creatinine clearance rate \< 30 mL/min)~* Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)~* Patients with any conditions not suitable for the trial (investigators' decision)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- MSD group (Type: EXPERIMENTAL): The patients will received HSCT from MSD.
- MUD group (Type: EXPERIMENTAL): The patients will received HSCT from MUD.
- HRD group (Type: EXPERIMENTAL): The patients will received HSCT from HRD.

Based on this trial design, predict the completion outcome and termination type (if applicable).